Advaxis (ADXS) Lifted to “Strong-Buy” at ValuEngine

Advaxis (NASDAQ:ADXS) was upgraded by research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, March 30th, ValuEngine reports.

Several other research analysts have also issued reports on ADXS. Zacks Investment Research upgraded shares of Advaxis from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research report on Wednesday, February 20th. HC Wainwright lowered shares of Advaxis from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 18th.

Shares of ADXS traded up $0.06 during mid-day trading on Friday, reaching $3.59. 203,661 shares of the stock traded hands, compared to its average volume of 385,828. The firm has a market capitalization of $19.44 million, a P/E ratio of -0.19 and a beta of 3.95. Advaxis has a 1 year low of $2.70 and a 1 year high of $30.60.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.43. The firm had revenue of $19.69 million during the quarter. Advaxis had a negative net margin of 140.12% and a negative return on equity of 101.51%. Research analysts forecast that Advaxis will post -2.4 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of ADXS. Vanguard Group Inc lifted its stake in Advaxis by 48.3% in the third quarter. Vanguard Group Inc now owns 2,630,658 shares of the biotechnology company’s stock worth $2,473,000 after purchasing an additional 857,026 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Advaxis by 173.0% during the third quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock valued at $1,120,000 after acquiring an additional 755,352 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Advaxis by 5,970.3% during the fourth quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 553,031 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Advaxis by 2,468.2% during the fourth quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 355,415 shares during the last quarter. Finally, Virtu Financial LLC raised its stake in shares of Advaxis by 740.4% during the fourth quarter. Virtu Financial LLC now owns 176,213 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 155,246 shares during the last quarter.

Advaxis Company Profile

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Further Reading: Systematic Risk and Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.